Igor Makhlin, MD, discusses the evolving role of FES-PET/CT as a tool to aid in the diagnosis and management of estrogen receptor–positive breast cancer.
Igor Makhlin, MD
Advertisement
Igor Makhlin, MD, is an assistant professor of clinical medicine in the Division of Hematology-Oncology in the Department of Medicine at the University of Pennsylvania Perelman School of Medicine, as well as clinical leader of Flatiron Assist Breast Pathways and director of the Metastatic Tumor Board at Penn Medicine.
Articles by Igor Makhlin, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
5